WO2002018320A2 - INHIBITORS OF α4 MEDIATED CELL ADHESION - Google Patents
INHIBITORS OF α4 MEDIATED CELL ADHESION Download PDFInfo
- Publication number
- WO2002018320A2 WO2002018320A2 PCT/US2001/026594 US0126594W WO0218320A2 WO 2002018320 A2 WO2002018320 A2 WO 2002018320A2 US 0126594 W US0126594 W US 0126594W WO 0218320 A2 WO0218320 A2 WO 0218320A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- dimethoxy
- phenylalanine
- formula
- Prior art date
Links
- 0 COc1cc(*O*)cc(OC)c1-c1ccc(C[C@@](C(O*)=O)NC(c2c(*I)cccc2*)=O)cc1 Chemical compound COc1cc(*O*)cc(OC)c1-c1ccc(C[C@@](C(O*)=O)NC(c2c(*I)cccc2*)=O)cc1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Definitions
- the present invention relates to novel phenylalanine derivatives that are inhibitors of ⁇ 4 (including ⁇ 4 ⁇ 7 and 4 ⁇ x ) mediated adhesion which could be useful in treating conditions such as asthma, diabetes, rheumatoid arthritis, inflammatory bowel disease and other diseases involving leukocyte infiltration to the gastrointestinal tract or other epithelial lined tissues; such as, skin, urinary tract, respiratory airway and joint synovium.
- the inhibitors of the present invention could also be useful in treating conditions involving leukocyte infiltration to other tissues including lung, blood vessels, heart and nervous system as well as transplanted organs such as kidney, liver, pancreas, heart and intestine, and blood vessels.
- the adhesion of leukocyte to endothelial cells or extracellular matrix proteins is a fundamental process for immunity and inflammation and involves multiple adhesive interactions.
- the earliest events in this process include leukocyte rolling followed by changes in integrin avidity, which lead to subsequent firm adhesion (for reviews see Butcher, Cell 67:1033-1036 (1991); Harlan, Blood 3 : 513-525 (1985); Hemler, Annu . Rev. Immunol . 8:365-400 (1990); Osborn, Cell 62:3-6 (1990); Shimizu et al . , Immunol . Rev. 114:109-143 (1990); Springer, Nature 346:425-434 (1990); and Springer, Cell 76:301- 314 (1994) ) .
- the leukocytes In response to chemotactic factors, the leukocytes must migrate through two adjacent endothelial cells and into tissues that are composed, in part, of the extracellular matrix protein fibronectin (FN) (see ayner et al . , J. Cell Biol . 105:1873-1884 (1987)) and collagen (CN) (see Bornstein et al . , Ann. .Rev. Biochem . 49:957-1003 (1980); and Miller, Chemistry of the collagens and their distribution, in "Extracellular Matrix Biochemistry", K.A. Piez and A.H. Reddi, editors, Elsevier, Amsterdam, 41-78 (1983)).
- FN extracellular matrix protein fibronectin
- CN collagen
- Integrins are heterodimers composed of non-covalently associated subunits, referred to as the alpha ( ⁇ ) and beta ( ⁇ ) subunits (for reviews see Hemler, Annu. .Rev. Immunol . 8:365-400 (1990); Hynes, Cell 48:549-554 (1987); Shimizu et al . , Immunol . .Rev. 114:109-143 (1990); and Springer, Nature 346:425-434
- VLA-4 Very Late Antigen-4
- VCAM-1 vascular cell adhesion molecule-1
- CS-1 an alternatively spliced region of the FN A chain (Wayne et al., J “ . Cell Biol . 109:1321-1330 (1989)).
- the ⁇ 7 integrin subunit first cloned by Erie et al . (Erie et al . , J. Biol . Chem. 266:11009-11016 (1991)), is expressed only on leukocytes and is known to associate with two distinct ⁇ subunits, ⁇ 4 (Ruegg et al., J “ . Cell Biol . 117:179-189 (1992)) and ⁇ E (Cerf-Bensussan et al., Eur. J. Immunol .
- the ⁇ 4 ⁇ 7 complex has three known ligands (VCAM-1, CS-1, MAdCAM-1) .
- VCAM-1, CS-1, MAdCAM-1 One ligand which shows unique specificity for ⁇ 4 ⁇ 7 is Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) (see Andrew et al . , J “ . Immunol . 153:3847-3861 (1994); Briskin et al . , Nature 363:461-464 (1993); and Shyjan et al . , J. Immunol .
- MAdCAM-1 is highly expressed on Peyer's patch high endothelial venules, in mesenteric lymph nodes, and on gut lamina intestinal and mammary gland venules (Berg et al . , Immunol . Rev. 105:5-18 (1989)). Integrin ⁇ 4 ⁇ 7 and MAdCAM-1 have been shown to be important in regulating lymphocyte trafficking to normal intestine (Holzmann et al . , Cell 56:37-46 (1989)).
- the second ligand for ⁇ 4 ⁇ 7 is CS-1 (see Guan et al . , Cell 60:53-61 (1990); and Wayner et al . , J “ . Cell Biol . 109:1321-1330 (1989) ) .
- the cell-binding site within CS-1 is composed of 25 amino acids where the carboxy terminal amino acid residues,
- EILDVPST form the recognition motif (see Komoriya et al . , J “ . Biol . Chem . 266:15075-15079 (1991); and Wayner et al . , J “ . Cell Biol . 116:489-497 (1992)).
- VCAM-1 vascular cell adhesion molecule-1
- CS-1 vascular cell adhesion molecule-1
- Leukocyte adhesion to inflamed synovium was suggested to be dominated by ⁇ /VGAM-l interactions, however, increased numbers of ⁇ 4 ⁇ 7 positive T cells were also found in the synovial membrane of rheumatoid arthritis patients (McMurray, Semin . Arthri tis Rheum. 25:215-233 (1996)) and it was suggested that the augmented expression of 4 ⁇ 7 may contribute to the development and perpetuation of this disease (see Lazarovits et al . , J.
- monoclonal antibodies to 4 were effective in several lung antigen challenge models such as ovalbumin-induced asthma in mice, rats and guinea-pigs (See Pretolani et al . , J “ . Exp. Med. 180: 795-805 (1994), Fryer et al., J “ . Clin . Invest . 99:2036-2044 (1997); and Henderson et al . , J “ . Clin . Invest . 100: 3083-3092 (1997)).
- an orally bioavailable, non-peptide small molecule antagonist of ⁇ 4 could be useful in treating or preventing conditions such as asthma, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis and other diseases (see W099/36393) .
- the objective here was to define an orally bioavailable and potent small molecule antagonist of 4 integrins.
- Small molecules that are potent inhibitors of ⁇ 4 mediated adhesion to either MAdCAM-1, VCAM-1, or CS-1 and which could be useful for the treatment or prevention of inflammatory diseases and/or allergic diseases are disclosed.
- the present invention relates to a novel phenylalanine derivative of Formula [I] :
- X 1 is a halogen atom
- X 2 is a halogen atom
- Q is a -CH 2 - group or a -(CH 2 ) 2 - group
- Y is a C 1 _ 6 alkyl group
- C0 2 R is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.
- the present invention also relates to a pharmaceutical composition comprising t erapeutically effective amount of a compound of Formula [I] or a pharmaceutically acceptable salt thereof .
- the present invention also relates to a method for treating or preventing conditions caused by ⁇ 4 integrins
- the compound of the present invention may exist in the form of optical isomers based on the asymmetric atom thereof, and the present invention includes these optical isomers and mixtures thereof.
- a carboxyl group which may be esterified includes a carboxyl group and an esterified carboxyl group which may be hydrolyzed in a body to afford a carboxyl group.
- esterified carboxyl group are a substituted or unsubstituted C 2 _ 7 alkoxycarbonyl group such as methoxycarbonyl group, benzyloxycabonyl group, p- aminobenzyloxycarbonyl group and the like.
- the R/S configuration of a bond need not be fixed.
- the compound of the present invention may be a compound with a sole configuration or a mixture with different configurations.
- preferable compounds are compounds of Formula [I-l] :
- X 1 is chlorine atom or fluorine atom
- X 2 is chlorine atom or fluorine atom
- Y is a C 1 _ i alkyl group
- C0 2 R is a carboxyl group or a C 2 _ 7 alkoxycarbonyl group .
- X 1 is chlorine atom or fluorine atom
- X 2 is chlorine atom or fluorine atom
- Q is a -CH 2 - group
- Y is methyl group, ethyl group, or n-propyl group
- C0 2 R is a carboxyl group, methoxycarbonyl group, ethoxycarbonyl group, or tert- butoxycarbonyl group .
- Especially preferable compounds are compounds of Formula [I-l] wherein X 1 is fluorine atom, X 2 is chlorine or fluorine atom, Q is a -CH 2 - group, Y is methyl or ethyl group, and C0 2 R is a carboxyl group or a C 2 . 7 alkoxycarbonyl group such as methoxycarbonyl group and ethoxycarbonyl group .
- Most preferable compounds of the present invention may be selected from:
- the compound of the present invention may be used either in a free form or in a form of pharmaceutically acceptable salts thereof.
- Pharmaceutically acceptable salts include a salt with an inorganic base, an organic base or a basic amino acid (e.g., an alkali metal salt such as a sodium salt and a potassium salt; an alkali earth metal salt such as magnesium salt and calcium salt; or a salt with an amine such as an ammonium salt, triethylammonium salt, a salt with lysine and the like) and a salt with an inorganic acid or an organic acid (e.g., hydrochloride, sulfate, nitrate, hydrobromide, methanesulfonate, p-toluenesulfonate, acetate, maleate) .
- Pharmaceutically acceptable salts also include an intramolecular salt thereof, or a solvate or hydrate thereof, as well.
- the characteristics of the present compound are the introduction of a C x _ 6 alkoxy substituted C ⁇ alkyl group at the 4 ' -position of the biphenyl nucleus and the combination of the dihalo-substituted benzoyl group and 2 ' , 6 ' -di (C-_.. s alkoxy) -4 '- (C _ e alkoxy substituted C x _ 2 alkyl) iphenyl nucleus, where such characteristics are not specifically described in prior publications .
- the compound of the present invention has potent inhibitory activity against ⁇ 4 mediated cell adhesion, and shows excellent bioavailability after oral administration which reflects the overall improvement in: a) metabolic stability, b) plasma protein binding and c) aqueous solubility.
- the introduction of a C x _ e alkoxy substituted C x _ 2 alkyl group at the 4 ' -position of the biphenyl nucleus reduces the fast metabolism that was observed with some of the compounds described in prior publications.
- the compound of the present invention reduces hepatic clearance thereby improving the bioavailability.
- the compound of the present invention therefore, shows excellent in vivo improvements against the unfavorable conditions caused by the ⁇ 4 mediated cell adhesion.
- the compound of the present invention can be used for a method of treating or preventing ⁇ 4 (including ⁇ 4 ⁇ x and 4 ⁇ 7 ) adhesion mediated conditions in a mammal such as a human.
- the compound of the present invention can be used for a method of treating an individual (e.g., a mammal, such as a human or other primate) suffering from a disease associated with leukocyte (e.g., lymphocyte, monocyte) infiltration to tissues (including recruitment and/or accumulation of leukocytes in tissues) which express the molecule MAdCAM-1 and/or VCAM-1.
- a mammal such as a human or other primate
- leukocyte e.g., lymphocyte, monocyte
- tissues including recruitment and/or accumulation of leukocytes in tissues which express the molecule MAdCAM-1 and/or VCAM-1.
- inflammatory diseases including diseases which are associated with leukocyte infiltration to the gastrointestinal tract (including gut- associated endothelium) , other mucosal tissues, or tissues expressing the molecule MAdCAM-1 (e.g., gut-associated tissues, such as venules of the lamina intestinal of the small and large intestine; and mammary gland (e.g., lactating mammary gland)), can be treated according to the present method.
- an individual suffering from a disease associated with leukocyte infiltration to tissues as a result of binding of leukocytes to cells (e.g., endothelial cells) expressing the molecule VCAM-1 can be treated according to the present invention.
- the method for treating or preventing ⁇ 4 -dependent (including ⁇ 4 ⁇ i and ⁇ 4 ⁇ 7 ) adhesion mediated conditions or diseases associated with leukocyte infiltration may comprise administering to a mammal or a human patient an effective amount of the compound of the present invention in admixture with a pharmaceutically acceptable carrier or diluent .
- the compound of the present invention accordingly, can be used to treat or prevent such inflammatory conditions as rheumatoid arthritis (RA) ; asthma; allergic conditions such as rhinitis; adult respiratory distress syndrome; AIDS-dementia; Alzheimer's disease; cardiovascular diseases; thrombosis or harmful platelet aggregation; reocclusion following thrombolysis; reperfusion injury; psoriasis; skin inflammatory diseases such as eczema, contact dermatitis and atopic dermatitis; diabetes (e.g., insulin-dependent diabetes mellitus, autoimmune diabetes); multiple sclerosis; systemic lupus erythematosus (SLE) ; inflammatory bowel disease such as ulcerative colitis, Crohn's disease (regional enteritis) and pouchitis (for example, resulting after proctocolectomy and ileoanal anastomosis) ; diseases associated with leukocyte infiltration to the gastrointestinal tract such as Celiac disease, nontropical
- graft or graft vs. host diseases include intimal hyperplasia; arteriosclerosis (including graft arteriosclerosis after transplantation) ; reinfarction or restenosis after surgery such as percutaneous transluminal coronary angioplasty (PTCA) and percutaneous transluminal artery recanalization; nephritis; tumor angiogenesis; malignant tumor; multiple myeloma and myeloma-induced bone resorption; and central nervous system injury such as stroke, traumatic brain injury and spinal cord injury.
- PTCA percutaneous transluminal coronary angioplasty
- nephritis tumor angiogenesis
- malignant tumor multiple myeloma and myeloma-induced bone resorption
- central nervous system injury such as stroke, traumatic brain injury and spinal cord injury.
- the method can be preferably used for the treatment or prevention of asthma, allergic conditions such as rhinitis, inflammatory bowel disease such as ulcerative colitis and Crohn's disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis and rejection after transplantation.
- Compounds suitable for use in therapy can be evaluated in vivo, using suitable animal models. Suitable animal models of inflammation have been described in publications. For example, NOD mice provide an animal model of insulin-dependent diabetes mellitus.
- CD45RB Hl SCID mice model provide a model with similarity to both Crohn's disease and ulcerative colitis
- the compound of the present invention While it is possible for the compound of the present invention to be administered alone, it is preferable to present it as a pharmaceutical composition comprising a therapeutically effective amount of the compound of Formula [I] and a pharmaceutically acceptable carrier or diluent .
- the carrier must be acceptable in the sense of being not deleterious to the recipient thereof.
- the pharmaceutically acceptable carrier or diluent may be, for example, binders (e.g., syrup, gum arable, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone) , excipients (e.g., lactose, sucrose, corn starch, potassium phosphate, sorbitol, glycine) , lubricants (e.g., magnesium stearate, talc, polyethylene glycol, silica) disintegrators (e.g., potato starch), wetting agents (e.g., sodium laurylsulfate) , and the like.
- binders e.g., syrup, gum arable, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone
- excipients e.g., lactose, sucrose, corn starch, potassium phosphat
- the pharmaceutical compositions include those in a form suitable for oral, pulmonary, ophthalmic, rectal, parenteral (including subcutaneous, intramuscular, and intravenous) , intra- articular, topical, nasal inhalation (e.g., with an aerosol) or buccal administration. These formulations are understood to include long-acting formulations known in the art of pharmacy. Oral and parenteral administrations are preferred modes of administration .
- the pharmaceutical composition may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired form.
- compositions of the present invention suitable for oral administration may be in the form of discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the compound of the present invention, in the form of a powder or granules, or in the form of a solution or suspension in an aqueous liquid.
- Formulations for other uses could involve a nonaqueous liquid; in the form of an oil-in-water emulsion or a water-in-oil emulsion; in the form of an aerosol; or in the form of a cream or ointment or impregnated into a transdermal patch for use in administering the compound of the present invention transdermally, to a patient in need thereof.
- the compound of the present invention may also be administered to a patient in need thereof in the form of a bolus, electuary, or paste.
- the compound of the present invention can be administered to a patient in need thereof in amounts sufficient to reduce or prevent ⁇ 4 -mediated cell adhesion.
- the compound of the present invention can be administered to the patient in amounts sufficient to achieve the desired therapeutic and/or prophylactic effect, or amounts sufficient to reduce or prevent MAdCAM-l/ CAM-1 mediated binding to a MAdCAM-l/VCAM-1 ligand, thereby inhibiting leukocyte adhesion and infiltration and associated cellular responses.
- the compounds and compositions of the present invention can be administered to patients suffering from a condition listed herein before in an amount which is effective to fully or partially alleviate undesired symptoms of the condition.
- the symptoms may be caused by leukocyte adhesion or cell activation, which would typically be expected to occur as a result of increased VCAM-1 and/or MAdCAM-1 expression on the surface of endothelial cells.
- Increased VCAM-1, MAdCAM-1 and/or CS-1 expression can be due to a normal inflammation response or due to abnormal inflammatory states.
- an effective dose of a compound of the invention may reduce the increased cell adhesion due to increased VCAM-1 and/or MAdCAM-1 expression by endothelial cells.
- Reducing the adhesion observed in the disease state by 50% can be considered an effective reduction in adhesion. More preferably, a reduction in ex vivo adhesion by 90%, is achieved. Most preferably, adhesion mediated by VCAM-1, MAdCAM-1 and/or CS-1 interaction is abolished by an effective dose. Clinically, in some instances, effects of the compound can be observed as a decrease in leukocyte infiltration into tissues or sites of injury or inflammation. To achieve a therapeutic effectiveness, then, the compounds or compositions of the present invention are administered to provide a dose effective to reduce or eliminate leukocyte adhesion or cell activation to alleviate undesired symptoms.
- a suitable daily dose of the compound [I] , or a pharmaceutically acceptable salt thereof, for a mammalian subject suffering from, or likely to suffer from, any condition as described herein is from 0.1 to 100 mg per kilogram body weight of the mammalian subject, preferably 0.3 to 30 g/kg of mammal body weight. In the case of parenteral administration, the dose may be in the range of 0.1 to 10 mg of the compound per kilogram body weight, preferably 0.3 to 3 mg/kg of mammal body weight.
- a suitable (daily) dose may be in the range of 1 to 100 mg of the compound per kilogram body weight, but preferably 2 to 30 mg of the compound per kilogram, the most preferred dosage being 1 to 10 mg/kg of mammal body weight administered two to three times daily.
- a suitable dose of a compound of Formula [I] , or a pharmaceutically acceptable salt thereof may be in the range of 0.1 to 100 ⁇ g of the compound per kilogram.
- the compound of Formula [I] or a pharmaceutically acceptable salt thereof can be prepared by the steps comprising: (1) converting a compound of Formula [II] :
- C0 2 R x is an esterified carboxyl group, and the other symbols are the same as defined above,, into a compound of Formula [la] : wherein the symbols are the same as defined above, (2) converting the esterified carboxyl group of the compound [la] into a carboxyl group, if necessary, and (3) converting the resulting compound into a pharmaceutically acceptable salt thereof, if further desired.
- Step 1 The conversion of the compound [II] into the compound [la] can be carried out by one of the Methods A to D described hereinafter.
- Step 2 The conversion of the esterified carboxyl group CO-R 1 into a carboxyl group can be carried out by a conventional method, which is selected according to the type of the esterified carboxyl group to be converted, for example, hydrolysis using a base (e.g., an alkali metal hydroxide such as LiOH and NaOH) or an acid (e.g., HCl) , treatment with an acid (e.g., TFA) , and the like.
- a base e.g., an alkali metal hydroxide such as LiOH and NaOH
- an acid e.g., HCl
- TFA an acid
- Step 3 The conversion of the resulting compound [I] into a pharmaceutically acceptable salt thereof can be carried out by a conventional method using a base (e.g., inorganic base such as NaOH, organic base such as triethylamine or basic amino acid such as lysine) or an acid (e.g., inorganic acid such as HCl, HN0 3 and H 2 S0 4/ organic acid such as acetic acid and maleic acid, or acidic amino acid such as aspartic acid and glutamic acid) .
- a base e.g., inorganic base such as NaOH, organic base such as triethylamine or basic amino acid such as lysine
- an acid e.g., inorganic acid such as HCl, HN0 3 and H 2 S0 4/ organic acid such as acetic acid and maleic acid, or acidic amino acid such as aspartic acid and glutamic acid
- Step 1 The oxidation reaction can be carried out by a conventional method using an oxidizing agent with or without a base in a suitable solvent.
- the oxidizing agent can be selected from conventional oxidizing reagents such as Mn0 2 , S0 3 -pyridine, KMn0 4 , PCC, PDC and the like.
- the base can be selected from conventional organic bases such as trialkylamine (e.g., Et 3 N, DIEA) .
- trialkylamine e.g., Et 3 N, DIEA
- the solvent can be selected from any one which does not disturb the oxidation reaction, for example, halogenomethanes (e.g., CH 2 C1 2 , CHC1 3 ) , aromatic hydrocarbons (e.g., benzene, toluene), DMSO, H 2 0 or a mixture thereof.
- halogenomethanes e.g., CH 2 C1 2 , CHC1 3
- aromatic hydrocarbons e.g., benzene, toluene
- DMSO e.g., benzene, toluene
- H 2 0 a mixture thereof.
- the reaction can be carried out at a temperature of -50°C to 50°C, preferably at room temperature.
- Step 2 The condensation of the compound [III] with the compound [IV] can be carried out in the presence of a reducing agent and a dehydrating reagent in a solvent or without a solvent.
- the reducing agent can be selected from conventional reducing agents such as trialkylsilane (e.g., triethyl-silane) and the like.
- the dehydrating reagent includes sulfuric acid, trifluoroacetic acid and the like.
- the solvent can be selected from any one which does not disturb the reaction, for example, ethers (e.g., dioxane, THF) , aromatic hydrocarbons (e.g., benzene toluene), halogenomethanes (e.g., CH 2 C1 2 and CHC1 3 ) or a mixture thereof.
- ethers e.g., dioxane, THF
- aromatic hydrocarbons e.g., benzene toluene
- halogenomethanes e.g., CH 2 C1 2 and CHC1 3
- the compound [la] can be prepared by: (1) converting the compound [II] into a compound of Formula [V] :
- a halogen atom e.g., chlorine atom, bromine atom and iodine atom
- an alkanesulfonyloxy group e.g., a halogen atom, bromine atom and iodine atom
- arylsulfonyloxy group e.g., benzenesulfonyl group and p-toluenesulfonyl group
- arylsulfonyloxy group e.g., benzenesulfonyl group and p-toluenesulfonyl group
- Step 1 The conversion of the compound [II] into the compound [V] can be carried out by halogenating or sulfonylating the compound [II] .
- the halogenation reaction can be carried out by the conventional method using a halogenating reagent with or without a base in a suitable solvent .
- the halogenating reagent can be selected from the conventional halogenating reagents such as phosphorus trihalide
- phosphorous tribromide e.g., phosphorous tribromide, phosphorous trichloride
- a combination of tetrahalomethane e.g., CBr 4
- triphenylphosphine e.g., triphenylphosphine
- the base can be selected from conventional inorganic bases such as alkali metal carbonate (e.g., Na 2 C0 3/ K 2 C0 3 ) , alkali metal hydrogen carbonate (e.g., NaHC0 3; KHC0 3 ) and the like.
- alkali metal carbonate e.g., Na 2 C0 3/ K 2 C0 3
- alkali metal hydrogen carbonate e.g., NaHC0 3; KHC0 3
- the solvent can be selected from any one which does not disturb the condensation reaction, for example, halogenomethanes (e.g., CH 2 C1 2 , CHC1 3 ) , ethers (e.g., dioxane, diethyl ether, THF) , DMF, DMSO, or a mixture thereof.
- halogenomethanes e.g., CH 2 C1 2 , CHC1 3
- ethers e.g., dioxane, diethyl ether, THF
- DMF dioxane
- DMSO DMSO
- the reaction can be carried out at a temperature of -50°C to 50°C, preferably at 0°C to room temperature.
- the sulfonylation reaction can be carried out by the conventional method using a sulfonylating reagent with a base in a suitable solvent.
- the sulfonylating reagent can be selected from an alkanesulfonyl halide and an arylsulfonyl halide such as methanesulfonyl chloride, benzenesulfonyl chloride, p- toluenesulfonyl chloride and the like.
- the base can be selected from an organic base (e.g., trialkylamine such as Et 3 N, DIEA, DBU and 4-methyl morpholine, and pyridine) , an alkali metal carbonate (e.g., Na 2 C0 3 , K 2 C0 3 ) , an alkali metal hydrogen carbonate (e.g., NaHC0 3 , KHC0 3 ) , an alkali metal hydroxide (e.g., NaOH, KOH) , an alkaline earth metal hydroxide (e.g., Ba(OH) 2 ), and the like.
- organic base e.g., trialkylamine such as Et 3 N, DIEA, DBU and 4-methyl morpholine, and pyridine
- an alkali metal carbonate e.g., Na 2 C0 3 , K 2 C0 3
- an alkali metal hydrogen carbonate e.g., NaHC0 3 , KHC0 3
- an alkali metal hydroxide e
- the solvent can be selected from any one which does not disturb the reaction, for example, halogenomethanes (e.g., CH 2 C1 2 , CHC1 3 ) , ethers (e.g., dioxane, diethyl ether, THF), DMF, DMSO, or a mixture thereof.
- halogenomethanes e.g., CH 2 C1 2 , CHC1 3
- ethers e.g., dioxane, diethyl ether, THF
- DMF e.g., DMSO
- the reaction can be carried out at a temperature of -50°C to 50°C, preferably at -20°C to 0°C.
- Step 2 The reaction of the compound [V] with the compound
- [IV] can be carried out in the presence or absence of a base and/or a dehalogenation reagent such as a silver compound (e.g., silver (I) oxide (Ag 2 0) and silver oxide (AgO) ) (see Ortiz et al . , Synth . Commun . 23:749-756(1993)) in a suitable solvent or without a solvent .
- a dehalogenation reagent such as a silver compound (e.g., silver (I) oxide (Ag 2 0) and silver oxide (AgO)
- a suitable solvent e.g., a suitable solvent or without a solvent.
- the reaction can be carried out in the presence of a silver compound without a base in a suitable solvent.
- the base can be selected from conventional inorganic bases and organic bases such as alkali metal carbonate (e.g., Na 2 C0 3 , K 2 C0 3 ) , alkali metal hydrogen carbonate (e.g., NaHC0 3 , KHC0 3 ) , trialkylamine (e.g., Et 3 N) , pyridine and the like.
- alkali metal carbonate e.g., Na 2 C0 3 , K 2 C0 3
- alkali metal hydrogen carbonate e.g., NaHC0 3 , KHC0 3
- trialkylamine e.g., Et 3 N
- the solvent can be selected from any one which does not disturb the condensation reaction, for example, aromatic hydrocarbons (e.g., benzene, toluene), halogenomethanes (e.g., CH 2 C1 2/ CHC1 3 ) , ethers (e.g., dioxane, diethyl ether, THF), DMF, DMSO, MeCN, or a mixture thereof.
- aromatic hydrocarbons e.g., benzene, toluene
- halogenomethanes e.g., CH 2 C1 2/ CHC1 3
- ethers e.g., dioxane, diethyl ether, THF
- DMF dioxane
- DMSO DMSO
- MeCN MeCN
- the compound [la] can be prepared by alkylating the compound [II] with a compound of Formula [VI] :
- the alkylation can be carried out in the presence or absence of a base and/or a dehalogenation reagent such as silver compound (e.g., silver (I) oxide (Ag 2 0) and silver oxide (AgO)) (see Choi et al . , J " . Med. Chem. 39:1907-1916 (1996)) in a suitable solvent or without solvent .
- a dehalogenation reagent such as silver compound (e.g., silver (I) oxide (Ag 2 0) and silver oxide (AgO)
- the reaction can be carried out in a similar manner as described in the Step 2 of Method B.
- Method D Method D :
- the compound [la] can be prepared by condensing the compound [II] with the compound [IV] .
- the condensation reaction can be carried out in the presence of a dehydrating reagent in a suitable solvent or without solvent.
- the dehydrating reagent can be selected from conventional dehydrating reagents such as sulfuric acid, p- toluenesulfonic acid and the like.
- the solvent can be selected from any one which does not disturb the condensation reaction, for example, aromatic hydrocarbons (e.g., benzene, toluene), halogenomethanes (e.g., CH 2 C1 2 , CHC1 3 ) , ethers (e.g., dioxane, diethyl ether, THF), DMF, DMSO, MeCN, or a mixture thereof.
- aromatic hydrocarbons e.g., benzene, toluene
- halogenomethanes e.g., CH 2 C1 2 , CHC1 3
- ethers e.g., dioxane, diethyl ether, THF
- DMF DMSO
- MeCN MeCN
- the starting compound [II] can be prepared by one of the following methods (Methods E-G) .
- the compound [II] can be prepared by condensing a compound of Formula [VII] , a salt thereof or a reactive derivative thereof, with a compound of Formula [VIII] or a salt thereof.
- a salt of the compound [VII] and [VIII] includes, for example, a salt with an inorganic or organic acid (e.g., trifluoroacetate, hydrochloride, sulfate) , a salt with an inorganic base (e.g., an alkali metal salt such as a sodium salt or a potassium salt, an alkaline earth metal salt such as a barium salt or calcium salt) .
- the condensation reaction can be carried out by a conventional method applied for a usual peptide synthesis.
- the condensation reaction of the compound [VII] or a salt thereof with the compound [VIII] or a salt thereof can be carried out in the presence of a condensing reagent, with or without a base in a suitable solvent.
- the condensing reagent can be selected from any one which can be used for a conventional peptide synthesis, for example, BOP-Cl, BOP reagent, DCC, EDC or CDI.
- the condensing reagent can be used with an activator (e.g., HOBt) .
- the base can be selected from an organic base (e.g., DIEA,
- an alkali metal hydrogen carbonate e.g., Na 2 C0 3 , K 2 C0 3 .
- the solvent can be selected from any one which does not disturb the condensation reaction, for example, AcOEt, CHC1 3 , CH 2 C1 2 , THF, DMF, H 2 0 or a mixture thereof.
- the reaction can be carried out at a temperature of -50°C to 50°C, preferably at 0°C to room temperature.
- the condensation reaction of the compound [VIII] or a salt thereof with the reactive derivative of the compound [VII] is carried out in the presence or absence of a base in a solvent .
- Examples of the reactive derivative of the compound [VII] are an acid halide (e.g., an acid chloride), a reactive ester (e.g., an ester with p-nitrophenol) , an anhydride thereof, a mixed anhydride with other carboxylic acid (e.g., a mixed anhydride with acetic acid), and the like.
- an acid halide e.g., an acid chloride
- a reactive ester e.g., an ester with p-nitrophenol
- an anhydride thereof e.g., a mixed anhydride with other carboxylic acid (e.g., a mixed anhydride with acetic acid), and the like.
- the base can be selected from an organic base (e.g., DIEA, DMAP, DBU, Et 3 N) , an alkali metal carbonate (e.g., Na 2 C0 3 , K 2 C0 3 ) , an alkali metal hydroxide (e.g., NaOH, KOH) and the like.
- an organic base e.g., DIEA, DMAP, DBU, Et 3 N
- an alkali metal carbonate e.g., Na 2 C0 3 , K 2 C0 3
- an alkali metal hydroxide e.g., NaOH, KOH
- the solvent can be selected from any one which does not disturb the condensation reaction, for example, AcOEt, H 2 0, CHC1 3> CH 2 C1 2 , C 2 H 4 C1 2 , Et 2 0, THF, DMF, CH 3 CN, DMSO, benzene, toluene or a mixture thereof.
- the reaction can be carried out at a temperature of -30 °C to room temperature.
- the compound [II] can be prepared by reacting a compound of Formula [IX] with a compound of Formula [X] .
- Examples of the leaving group L may be a halogen atom and a trifluoromethanesulfonyloxy group.
- the coupling reaction can be carried out by a conventional aryl coupling method, e.g., Suzuki coupling method (for reference see: Suzuki et al . , Synth . Commun . 11:513 (1981);
- the coupling reaction can be carried out, for example, at a temperature of room temperature to 150 °C, preferably at a temperature of 80 °C to 150 °C, in the presence of a palladium catalyst (e.g., tetrakis (triphenylphosphine) -palladium, palladium(II) acetate, palladium(II) chloride) , a phosphine ligand (e.g., triphenylphosphine, triethyl phosphite, trimethyl phosphite, triisopropyl phosphite) and a base (e.g., K 2 C0 3 , Et 3 N, DIEA, Dabco, diisopropylamine, morpholine) in a suitable solvent .
- the solvent can be selected from any one which does not disturb the coupling reaction, for example, toluene, THF, DME, DMF, DMA, NMP,
- a compound of Formula [II] can be also prepared by:
- Step 1 The conversion of the compound [IX] to the corresponding organotin compound can be carried out, for example, by reacting the compound [IX] with a hexaalkylditin
- the solvent can be selected from any one which does not disturb the coupling reaction, for example, dioxane, toluene, DME, DMF, H 2 0 or a mixture thereof .
- Step 2 The coupling reaction can be carried out by a conventional aryl coupling method, e.g., Stille coupling method (for reference see: Stille et al . , Angew. Chem. Int . Ed. Engl . 25:508-524 (1986) ) .
- Stille coupling method for reference see: Stille et al . , Angew. Chem. Int . Ed. Engl . 25:508-524 (1986) ) .
- the coupling reaction can be carried out, for example, at a temperature of room temperature to 150 °C, preferably at a temperature of 80°C to 120 °C, in the presence of tetrakis (triphenylphosphine) palladium in a suitable solvent.
- the solvent can be selected from any one which does not disturb the coupling reaction, for example, toluene, DME, DMF, H 2 0 or a mixture thereof .
- the compound [IX] can be prepared by: (1) condensing a compound of Formula [XIII] :
- CO ⁇ 1 is the same as defined above, or a salt thereof, by a conventional method similar to Method E; and (2) converting the hydroxyl group of the resulting compound into a leaving group by a conventional method.
- the conversion of the hydroxyl group into trifluoromethanesulfonyloxy group can be carried out by using triflie anhydride at -30°C to 0°C in the presence of a base (e.g., pyridine, NEt 3 , DIEA) in a suitable solvent (e.g., CH 2 C1 2 , CHC1 3 , THF or a mixture thereof) .
- a base e.g., pyridine, NEt 3 , DIEA
- a suitable solvent e.g., CH 2 C1 2 , CHC1 3 , THF or a mixture thereof
- the compound [VIII] can be prepared by: (1) condensing a compound of Formula [XV] :
- P is a protecting group for an amino group and the other symbols are the same as defined above, with a compound [X] by a conventional aryl coupling method, and (2) removing the protecting group for the amino group of the resulting compound.
- the protecting group for the amino group can be selected from conventional protecting groups for an amino group, for example, a substituted or unsubstituted aryl-C 2 _ 7 alkoxycarbonyl group (e.g., benzyloxycarbonyl group, p-nitrobenzyloxycarbonyl group), a C 2 _ 7 alkoxycarbonyl group (e.g., tert-butoxycarbonyl group) and the like.
- the coupling reaction can be carried out in a similar manner as described for the reaction of the compound [IX] with the compound [X] in Method F.
- the removal of the protecting group for the amino group can be carried out by a conventional method, which is selected according to the type of the protecting group to be removed, for example, catalytic reduction using a catalyst (e.g., palladium on activated carbon), treatment with an acid (e.g., TFA, HCl) and the like.
- a catalyst e.g., palladium on activated carbon
- an acid e.g., TFA, HCl
- the compound [XV] wherein L is trifluoromethanesulfonyloxy group can be prepared by reacting the compound of Formula [XVI] :
- the compound [X] can be prepared by a conventional method (for reference, see: Kuivila et al . , J. Am . Chem . Soc . 83:2159 (1961) ; Gerrard, The Chemistry of Boron, Academic Press, New
- [X] can be prepared by: (1) reacting a compound of Formula [XVII] :
- Q is the same as defined above, with an alkyl lithium (e.g., n-BuLi) at a temperature of -100°C to room temperature in a suitable organic solvent (e.g., diethyl ether, THF or the mixture thereof) , (2) reacting the resulting compound with trimethyl borate at a temperature of -100°C to room temperature in a suitable organic solvent (e.g., diethyl ether, THF or the mixture thereof) , and (3) hydrolyzing the resulting compound by a conventional method.
- a suitable organic solvent e.g., diethyl ether, THF or the mixture thereof
- the hydrolysis can be carried out at 0°C to room temperature in a suitable solvent (e.g., diethyl ether, THF, dioxane, H 2 0 or the mixture thereof) in the presence of an acid (e.g., AcOH or citric acid) and water.
- a suitable solvent e.g., diethyl ether, THF, dioxane, H 2 0 or the mixture thereof
- an acid e.g., AcOH or citric acid
- a halogen atom means chlorine atom, fluorine atom, bromine atom or iodine atom.
- a C x _ s alkyl group means a straight, branched or cycloalkyl group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, n-butyl, isopropyl, cyclopropyl, tert-butyl and the like.
- a C 2 .
- 7 alkoxycarbonyl group means a straight, branched or cycloalkoxycarbonyl group having 2 to 7 carbon atoms, preferably 2 to 5 carbon atoms, such as methoxycarbonyl, ethoxycarbonyl, n- propoxycarbonyl , n-butoxycarbonyl, iso-propoxycarbonyl, cyclopropoxycarbonyl , tert-butoxycarbonyl and the like.
- BOP-Cl Bis (2-oxo-3-oxazolidinyl) phosphinic chloride
- BOP reagent Benzotriazol-1-yloxy-tris (dimethylamino) - phosphonium hexafluorophosphate
- DCC 1,3 -Dicyclohexylcarbodiimide
- EDC l-Ethyl-3- (3-dimethylaminopropyl) carbodiimide
- THF Tetrahydrofuran
- DMF N,N-Dimethylformamide
- DMSO Dimethyl sulfoxide
- DMA N,N-Dimethylacetamide
- NMP 1-Methyl-2 -pyrrolidone
- DIEA Diisopropylethylamine
- DMAP 4- (N,N-Dimethylamino)pyridine
- Example 1 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine ethyl ester.
- Pd(PPh 3 ) 4 (19.5 g) was added to the mixture and stirred at 80-90 °C under argon for 1 hour.
- the mixture was cooled, diluted with AcOEt and H 2 0, filtered through Celite and washed with AcOEt.
- the filtrate was diluted with H 2 0 and separated.
- the organic layer was washed with H 2 0 and brine, dried (Na 2 S0 4 ) , treated with charcoal and evaporated.
- Example 2 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine methyl ester.
- Example 4 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine ethyl ester.
- Example 5 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine .
- Example 4 The product obtained in Example 4 (210 mg) was converted into the title compound (139 mg) in a similar manner as described in Example 3. mp . 232-235 °C; IR (Nujol) 3336, 1717, 1685 cm “1 ; MS (ESI -Q1MS) m/z 516 (M-H) .
- Example 6 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4-n- propoxymethylphenyl) -L-phenylalanine ethyl ester.
- (1) To a solution of the product obtained in Example 1 -(5) or Reference Example 3- (3) (3.0 g) in CH 2 C1 2 (80 ml) containing PPh 3 (1.77 g) was added CBr 4 (2.8 g) at 0°C. The mixture was stirred at room temperature for 3 hours and evaporated.
- Example 7 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4-n- propoxymethylphenyl) -L-phenylalanine .
- Example 6 The product obtained in Example 6 (150 mg) was converted into the title compound (142 mg) in a similar manner as described in Example 3. mp. 183-186 °C; IR (Nujol) 1719, 1684 cm “ ⁇ - MS (APCI) m/z 544 (M-H) .
- Example 8 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4-iso- propoxymethylphenyl) -L-phenylalanine ethyl ester.
- the product obtained in Example 6- (1) (231 mg) was converted into the title compound (179 mg) in a similar manner as described in Example 6- (2) using iso-PrOH instead of n-PrOH.
- Example 9 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4-iso- propoxymethylphenyl) -L-phenylalanine .
- Example 10 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine ethyl ester.
- Example l-(4) (2.1 g) was acylated with 2 , 6-difluorobenzoyl chloride in a similar manner as described in Example 1 -(5) to give N- (2, 6-difluorobenzoyl) - 4- (2 , 6-dimethoxy-4-hydroxymethylphenyl) -L-phenylalanine ethyl ester (2.75 g) . mp . 70-72 °C; IR (Nujol) 3400, 3263, 1735, 1654, 1624 cm “1 ; MS (APCI) m/z 500 (M+H) .
- Example 11 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl ) -L-phenylalanine methyl ester.
- Example 2- (4) (1.00 g) was acylated with 2 , 6-difluorobenzoyl chloride to give N-(2,6- difluorobenzoyl) -4- (2 , 6-dimethoxy-4-hydroxymethylphenyl) -L- phenylalanine methyl ester (873 mg) in a similar manner as described in Example l-(5).
- IR (Nujol) 3257, 1743, 1655, 1624 cm “ 1 ; MS (APCI +Q1MS) m/z 503 (M+NH 4 ) , 486 (M+H) .
- the product obtained above (860 mg) was converted into the title compound (220 mg) in a similar manner as described in Example 2- (6) and (7).
- Example 12 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine .
- Example 10 The product obtained in Example 10 (200 mg) was hydrolyzed in a similar manner as described in Example 3 to give the title compound (160 mg) .
- the product obtained in Example 11 (220 mg) was also hydrolyzed in a similar manner as described in Example 3 to give the title compound (167 mg) . mp. 156-158°C; IR (Nujol) 1735, 1655 cm “1 ; MS (ESI) m/z 498 (M-H) .
- Example 13 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine ethyl ester.
- the product (1.41 g) obtained in Example 10- (1) or Reference Example 4- (3) was converted into N-(2,6- difluorobenzoyl) -4- (2 , 6-dimethoxy-4-bromomethylphenyl) -L- phenylalanine ethyl ester (1.22 g) in a similar manner as described in Example 6-(l).
- Example 14 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine .
- Example 13 The product obtained in Example 13 (96 mg) was hydrolyzed in a similar manner as described in Example 3 to give the title compound (62 mg) .
- Example 15 N- (2 , 6-Difluorobenzoyl) -4- (2, 6-dimethoxy-4-n- propoxymethylphenyl) -L-phenylalanine ethyl ester.
- the product obtained in Example 13- (1) was converted into the title compound in a similar manner as described in Example 6-(2).
- Example 16 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4-iso- propoxymethylphenyl) -L-phenylalanine ethyl ester.
- Example 13- (1) The product obtained in Example 13- (1) was converted into the title compound in a similar manner as described in Example 6- (2) using iso-PrOH instead of n-PrOH.
- Example 17 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4-n- propoxymethylphenyl) -L-phenylalanine .
- Example 15 The product obtained in Example 15 was hydrolyzed in a similar manner as described in Example 3 to give the title compound.
- Example 18 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4-iso- propoxymethylphenyl) -L-phenylalanine .
- Example 16 The product obtained in Example 16 was hydrolyzed in a similar manner as described in Example 3 to give the title compound.
- Example 19 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine ethyl ester .
- Example l-(4) To a solution of the product obtained in Example l-(4) (863 mg) and 2-chloro-6-fluorobenzoic acid (456 mg) in DMF (15 ml) were added EDC»HC1 (549 mg) , HOBt (383 mg) and 4- methylmorpholine (0.48 ml) successively at room temperature. The mixture was stirred at room temperature for 14 hours and diluted with H 2 0. The mixture was extracted with AcOEt and the organic layer was sequentially washed with saturated aqueous NaHC0 3 , H 2 0 and brine. The resulting organic layer was dried (Na 2 S0 4 ) and evaporated.
- Example 20 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine .
- Example 19 To a solution of the product obtained in Example 19 (210 mg) in THF (5 ml) were added 0.5N LiOH (1.54 ml) and 3% H 2 0 2 (65 ⁇ l) at 5°C. The mixture was stirred at 5°C for 14 hours and acidified with 1 N HCl. The mixture was concentrated, diluted with H 2 0 and the resulting precipitate was collected by filtration and washed with H 2 0 to yield the title compound (171 mg) . mp. 182-184°C; IR (Nujol) 3295, 1729, 1711, 1653 cm “1 ; MS (ESI) m/z 514 (M-H) .
- Example 21 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine methyl ester.
- Example 2- (4) (49 g) was acylated with 2-chloro-6-fluorobenzoic acid to give N-(2-chloro- 6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4-hydroxymethylphenyl) -L- phenylalanine methyl ester (58 g) in a similar manner as described in Example 19-(1) .
- Example 22 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine ethyl ester.
- Example 19- (1) or Reference Example 5- (3) (3.29 g) was converted into N- (2-chloro-6- fluorobenzoyl) -4- (2 , 6-dimethoxy-4-bromomethylphenyl) -L- phenylalanine ethyl ester (2.91 g) in a similar manner as described in Example 6-(l) .
- IR (Neat+CHC1 3 ) 3315, 1735, 1662, 1603 cm "1 ; MS (APCI) m/z 582, 580, 578 (M+H) .
- Example 23 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4- methoxymethylphenyl) -L-phenylalanine.
- Example 22 The product obtained in Example 22 (130 mg) was hydrolyzed in a similar manner as described in Example 3 to give the title compound (100 mg) . mp. 170-175°C; IR (Nujol) 1720, 1680 cm “1 ; MS
- Example 21 (ESI) m/z 500 (M-H) .
- the product obtained in Example 21 (27.9 g) was also converted into the title compound (25.3 g) in a similar manner.
- Example 24 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4-n- propoxymethylphenyl) -L-phenylalanine ethyl ester.
- the product obtained in Example 22- (1) was converted into the title compound in a similar manner as described in Example
- Example 25 N- (2-Chloro-6-fluorobenzoyl) -4- (2, 6-dimethoxy-4-iso- propoxymethylphenyl) -L-phenylalanine ethyl ester.
- Example 22- (1) The product obtained in Example 22- (1) was converted into the title compound in a similar manner as described in Example 2- (7) using iso-PrOH instead of EtOH.
- IR Neat+CHC1 3 ) 3305, 1737, 1665, 1605 cm “1 ; MS (APCI) m/z 558 (M+H) .
- Example 26 N- (2-Chloro-6-fluorobenzoyl) -4- (2 , 6-dimethoxy-4-n- propoxymethylphenyl) -L-phenylalanine .
- the product obtained in Example 24 was hydrolyzed in a similar manner as described in Example 3 to give the title compound.
- Example 27 N- (2-Chloro-6-fluorobenzoyl) -4- (2, 6-dimethoxy-4-iso- propoxymethylphenyl) -L-phenylalanine .
- Example 25 The product obtained in Example 25 was hydrolyzed in a similar manner as described in Example 3 to give the title compound.
- Example 28 N- (2 , 6-Dichlorobenzoyl) -4- [2 , 6-dimethoxy-4- (2- ethoxyethyl) phenyl] -L-phenylalanine tert-butyl ester.
- Example 29 N- (2 , 6-Dichlorobenzoyl) -4- [2 , 6-dimethoxy-4- (2- ethoxyethyl) phenyl] -L-phenylalanine .
- Example 28 To a solution of the product obtained in Example 28 (109 mg) in CH 2 C1 2 (2 ml) was added 4N HCl-dioxane (3 ml) at room temperature . The mixture was stirred at room temperature for 3 days and evaporated. The residue was purified by column chromatography (silica gel; eluent: n-hexane/AcOEt 1:1) to yield the title compound (88 mg) .
- Example 30 N- (2 , 6-Difluorobenzoyl) -4- [2 , 6-dimethoxy-4- (2- ethoxyethyl) phenyl] -L-phenylalanine tert-butyl ester.
- Example 31 N- (2 , 6-Difluorobenzoyl) -4- [2 , 6-dimethoxy-4- (2- ethoxyethyl) phenyl] -L-phenylalanine .
- Example 30 The product obtained in Example 30 (200 mg) was hydrolyzed in a similar manner as described in Example 29 to give the title compound (161 mg) . mp. 63-70 °C; IR (Nujol) 1737, 1660, 1624 cm “ ; MS (APCI) m/z 512 (M-H) .
- Example 32 N- (2 , 6-Difluorobenzoyl) -4- [2 , 6-dimethoxy-4- (2- methoxyethyl) phenyl] -L-phenylalanine ethyl ester.
- Example l-(2) (43.83 g) was converted in a similar manner as described in Example 28- (3) into N- (tert-butoxycarbonyl) -4- [2, 6-dimethoxy-4- (2- hydroxyethyl) phenyl] -L-phenylalanine ethyl ester (38.03 g) .
- Example 33 N- (2 , 6-Difluorobenzoyl) -4- [2 , 6-dimethoxy-4- (2- methoxyethyl) phenyl] -L-phenylalanine .
- Example 32 The product obtained in Example 32 (187 mg) was hydrolyzed in a similar manner as described in Example 3 to give the title compound (143 mg) .
- Example 34 N- (2 , 6-Dichlorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine ethyl ester.
- Example 1 The title compound in Example 1 was also obtained by the following alternative route.
- Example 1 The title compound in Example 1 was also obtained by the following alternative route.
- Example l-(5) or Reference Example 3- (3) To a suspension of the product obtained in Example l-(5) or Reference Example 3- (3) (532 mg) in EtOH (10 ml) was added sulfuric acid (1 ml) . The mixture was stirred under reflux for 24 hours. The resulting mixture was cooled, diluted with H 2 0 and extracted with AcOEt. The organic layer was washed with H 2 0, brine, dried (Na 2 S0 4 ) and evaporated. The residue was purified by column chromatography (silica gel; eluent: n-hexane/AcOEt 2:1) to yield the title compound (476 mg) .
- Example 36 N- (2 , 6-Difluorobenzoyl) -4- (2 , 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine ethyl ester.
- the title compound in Example 10 was also obtained by the following alternative route.
- Example 10- (1) or Reference Example 4- (3) (73.4 g) was sulfonylated in a similar manner as described in Example 34- (1) to give N- (2 , 6-difluorobenzoyl) -4- (2 , 6-dimethoxy-4-methanesulfonyloxymethylphenyl) -L-phenylalanine ethyl ester (77.7 g) . mp. 125-126 °C; IR (Nujol) 3335, 2922, 2853, 1756, 1735, 1653, 1625, 1583, 1525, 1464 cm “1 ; MS (APCI) m/z 595 (M+NH 4 ) .
- Example 37 N- (2-Chloro-6-fluorobenzoyl) -4- (2, 6-dimethoxy-4- ethoxymethylphenyl) -L-phenylalanine ethyl ester.
- the title compound in Example 19 was also obtained by the following alternative route.
- Example 19- (1) The product obtained in Example 19- (1) or Reference Example 5- (3) (12.4 g) was sulfonylated in a similar manner as described in Example 34- (1) to give N- (2-chloro-6- fluorobenzoyl) -4- (2 , 6-dimethoxy-4- methanesulfonyloxymethylphenyl) -L-phenylalanine ethyl ester (14.0 g) . mp. 104-107 °C; IR (Nujol) 3286, 1734, 1655, 1605, 1583, 1541, 1460 cm "1 ; MS (APCI) m/z 611 (M+NH 4 ) .
- Reference Example 1 2 , 6-Dimethoxy-4-hydroxymethylbenzene boronic acid.
- 5-dimethoxybenzyl alcohol 80 g
- THF THF (1900 ml)
- n-BuLi 1.6 M in n-hexane, 750 ml
- the mixture was warmed up to room temperature for 2 hours and cooled again to - 60 °C.
- (MeO) 3 B 200 ml
- the resulting mixture was warmed to room temperature and stirred over night.
- Example l-(5) The compound in Example l-(5) was also obtained by the following alternative route.
- N- (2 , 6-Dichlorobenzoyl) -L-tyrosine ethyl ester (171.4 g) was obtained in a similar manner as described in Example 1- (5) from L-tyrosine ethyl ester hydroehloride (110.0 g) . mp. 141-142 °C; IR (Nujol) 3381, 3329, 1718, 1659 cm “1 ; MS (APCI) m/z 382 (M+H) .
- Example 10- (1) The compound in Example 10- (1) was also obtained by the following alternative route.
- L-Tyrosine ethyl ester hydroehloride (10.0 g) was acylated with 2, 6-difluorobenzoyl chloride in a similar manner as described in Example l-(5) to give N- (2, 6-difluorobenzoyl) -L- tyrosine ethyl ester (13.2 g) .
- Example 19- (1) The title compound in Example 19- (1) was also obtained by the following alternative route.
Abstract
Description
Claims
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU8677801A AU8677801A (en) | 2000-08-31 | 2001-08-27 | Inhibitors of alpha4 mediated cell adhesion |
NZ524043A NZ524043A (en) | 2000-08-31 | 2001-08-27 | Inhibitors of alpha4 mediated cell adhesion |
IL15430501A IL154305A0 (en) | 2000-08-31 | 2001-08-27 | INHIBITION OF alpha4 MEDIATED CELL ADHESION |
PL365668A PL206656B1 (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF α4 MEDIATED CELL ADHESION |
HU0302693A HUP0302693A3 (en) | 2000-08-31 | 2001-08-27 | Phenylalanin-derivatives, integrin inhibitors of alpha4, their use and process for their preparation |
DE60109943T DE60109943T2 (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF THE ALPHA 4-MEDIATED CELL ADHESION |
US10/333,985 US7026501B2 (en) | 2000-08-31 | 2001-08-27 | Inhibitors of α4 mediated cell adhesion |
CA 2418054 CA2418054C (en) | 2000-08-31 | 2001-08-27 | Inhibitors of .alpha.4 mediated cell adhesion |
DK01966246T DK1315694T3 (en) | 2000-08-31 | 2001-08-27 | Inhibitors of alpha-4-mediated cell adhesion |
SI200130351T SI1315694T1 (en) | 2000-08-31 | 2001-08-27 | Inhibitors of alpha 4 mediated cell adhesion |
AT01966246T ATE292615T1 (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF ALPHA 4-MEDIATED CELL ADHESION |
EP01966246A EP1315694B1 (en) | 2000-08-31 | 2001-08-27 | Inhibitors of alpha 4 mediated cell adhesion |
KR10-2003-7001993A KR100528049B1 (en) | 2000-08-31 | 2001-08-27 | Inhibitors of α4 mediated cell adhesion |
MXPA03001837A MXPA03001837A (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF alpha4 MEDIATED CELL ADHESION. |
AU2001286778A AU2001286778B2 (en) | 2000-08-31 | 2001-08-27 | Inhibitors of alpha4 mediated cell adhesion |
JP2002523438A JP3899022B2 (en) | 2000-08-31 | 2001-08-27 | α4-mediated cell adhesion inhibitor |
BR0113629-1A BR0113629A (en) | 2000-08-31 | 2001-08-27 | Alpha4-mediated cell adhesion inhibitors |
IL154305A IL154305A (en) | 2000-08-31 | 2003-02-05 | Phenylalanine derivatives, pharmaceutical compositions comprising same and methods of preparation |
NO20030885A NO327861B1 (en) | 2000-08-31 | 2003-02-25 | Phenylalanine derivatives which are inhibitors of <alpha> 4 controlled cell adhesion, processes for the preparation of the derivatives, pharmaceutical compositions containing the derivatives and their use for the preparation of drugs |
HK03105043.3A HK1052684B (en) | 2000-08-31 | 2003-07-11 | Inhibitors of alpha 4 mediated cell adhesion |
US12/247,129 US7671090B2 (en) | 2000-08-31 | 2008-10-07 | Inhibitors of α4 mediated cell adhesion |
US12/683,648 US7872151B2 (en) | 2000-08-31 | 2010-01-07 | Inhibitors of α4 mediated cell adhesion |
US12/962,707 US8501809B2 (en) | 2000-08-31 | 2010-12-08 | Inhibitors of α4 mediated cell adhesion |
US13/934,405 US20130289109A1 (en) | 2000-08-31 | 2013-07-03 | Inhibitors of alpha4 mediated cell adhesion |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22912800P | 2000-08-31 | 2000-08-31 | |
US60/229,128 | 2000-08-31 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10333985 A-371-Of-International | 2001-08-27 | ||
US11/179,729 Division US7456217B2 (en) | 2000-08-31 | 2005-07-13 | Inhibitors of alpha4 mediated cell adhesion |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002018320A2 true WO2002018320A2 (en) | 2002-03-07 |
WO2002018320A3 WO2002018320A3 (en) | 2002-06-06 |
Family
ID=22859926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/026594 WO2002018320A2 (en) | 2000-08-31 | 2001-08-27 | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Country Status (28)
Country | Link |
---|---|
US (6) | US7026501B2 (en) |
EP (1) | EP1315694B1 (en) |
JP (1) | JP3899022B2 (en) |
KR (1) | KR100528049B1 (en) |
CN (1) | CN1229334C (en) |
AR (1) | AR034556A1 (en) |
AT (1) | ATE292615T1 (en) |
AU (2) | AU2001286778B2 (en) |
BR (1) | BR0113629A (en) |
CA (1) | CA2418054C (en) |
CZ (1) | CZ303460B6 (en) |
DE (1) | DE60109943T2 (en) |
DK (1) | DK1315694T3 (en) |
ES (1) | ES2240509T3 (en) |
HK (1) | HK1052684B (en) |
HU (1) | HUP0302693A3 (en) |
IL (2) | IL154305A0 (en) |
MX (1) | MXPA03001837A (en) |
MY (1) | MY129000A (en) |
NO (1) | NO327861B1 (en) |
NZ (1) | NZ524043A (en) |
PL (1) | PL206656B1 (en) |
PT (1) | PT1315694E (en) |
RU (1) | RU2250895C2 (en) |
SI (1) | SI1315694T1 (en) |
TW (1) | TWI224587B (en) |
WO (1) | WO2002018320A2 (en) |
ZA (1) | ZA200301039B (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072536A1 (en) * | 2002-02-28 | 2003-09-04 | Tanabe Seiyaku Co., Ltd. | A process for preparing a phenylalanine derivative and intermediates thereof |
WO2004014844A2 (en) * | 2002-08-09 | 2004-02-19 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
WO2004037822A1 (en) * | 2002-10-22 | 2004-05-06 | Eisai Co., Ltd. | 7-phenyl pyrazolopyridine compounds |
WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
WO2005014533A2 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2006068058A1 (en) | 2004-12-20 | 2006-06-29 | Eisai R & D Management Co., Ltd. | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine |
US7091215B2 (en) | 2001-04-27 | 2006-08-15 | Eisai Co., Ltd. | Pyrazolo[1,5-a]pyridines and medicines containing the same |
US7153963B2 (en) | 2000-08-18 | 2006-12-26 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2007060408A2 (en) * | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
WO2007074456A2 (en) * | 2005-12-29 | 2007-07-05 | Yeda Research And Development Co.Ltd. | Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids |
WO2007091046A1 (en) * | 2006-02-09 | 2007-08-16 | Astrazeneca Ab | Chemical compounds |
WO2007089335A3 (en) * | 2005-12-29 | 2007-10-11 | Lexicon Genetics Inc | Multicyclic amino acid derivatives and methods of their use |
US7345049B2 (en) | 2003-12-22 | 2008-03-18 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US7410971B2 (en) | 2004-12-24 | 2008-08-12 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic)substituted benzene compounds |
US7425554B2 (en) | 2003-12-26 | 2008-09-16 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic)substituted benzene compounds |
US7732614B2 (en) | 2005-06-09 | 2010-06-08 | Ucb S.A. | 2,6-quinolinyl derivatives, processes for preparing them and their uses |
US7772249B2 (en) | 2001-02-08 | 2010-08-10 | Eisai R&D Management Co., Ltd. | Imidazo[1,2-b]pyridazine compound |
WO2011048091A1 (en) | 2009-10-21 | 2011-04-28 | Glaxo Group Limited | Process for preparing a phenylalanine derivative |
US8431603B2 (en) | 2008-04-15 | 2013-04-30 | Eisai R&D Management Co., Ltd. | 3-phenylpyrazolo[5,1-b]thiazole compounds |
US8530504B2 (en) | 2009-10-08 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Pyrazolothiazole compound |
US8808698B2 (en) * | 2006-02-03 | 2014-08-19 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
US11116760B2 (en) | 2018-10-30 | 2021-09-14 | Gilead Sciences, Inc. | Quinoline derivatives |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7419666B1 (en) | 2004-02-23 | 2008-09-02 | Massachusetts Eye And Ear Infirmary | Treatment of ocular disorders |
US7855291B2 (en) | 2005-12-29 | 2010-12-21 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
US7897763B2 (en) | 2005-12-29 | 2011-03-01 | Lexicon Pharmaceuticals, Inc. | Process for the preparation of substituted phenylalanines |
EP2007392A4 (en) * | 2006-02-28 | 2010-04-07 | Elan Pharm Inc | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
JP2009528359A (en) | 2006-02-28 | 2009-08-06 | エラン ファーマシューティカルズ,インコーポレイテッド | Methods of treating inflammatory and autoimmune diseases with natalizumab |
CA2644110A1 (en) | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
MX2010001938A (en) * | 2007-08-24 | 2010-03-11 | Lexicon Pharmaceuticals Inc | Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)p yrimidine-based compounds. |
US11287423B2 (en) | 2010-01-11 | 2022-03-29 | Biogen Ma Inc. | Assay for JC virus antibodies |
RS63744B1 (en) | 2010-01-11 | 2022-12-30 | Biogen Ma Inc | Assay for jc virus antibodies |
US20150010563A1 (en) * | 2012-02-21 | 2015-01-08 | Massachusetts Eye & Ear Infirmary | Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders |
US10119976B2 (en) | 2013-05-28 | 2018-11-06 | Biogen Ma Inc. | Method of assessing risk of PML |
WO2018085552A1 (en) * | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999036393A1 (en) * | 1998-01-20 | 1999-07-22 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK148576A (en) | 1975-04-18 | 1976-10-19 | Boehringer Mannheim Gmbh | PHENYLALCANCARBONIC ACID DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION |
JPH09504302A (en) | 1993-11-01 | 1997-04-28 | 日本チバガイギー株式会社 | Endothelin receptor antagonist |
MX9604368A (en) | 1994-03-28 | 1997-12-31 | Ciba Geigy Japan Ltd | Antagonists of endothelin receptors. |
US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
EP0821670A1 (en) | 1995-04-21 | 1998-02-04 | Novartis AG | N-aroylamino acid amides as endothelin inhibitors |
DE69833654T2 (en) | 1997-05-29 | 2006-12-14 | Merck & Co., Inc. (A New Jersey Corp.) | BIARYL ALKANIC ACIDS IN USE AS CELL ADHESION INHIBITORS |
JP2002501537A (en) | 1997-05-29 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | Sulfonamides as cell adhesion inhibitors |
WO1998053814A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
ATE256699T1 (en) | 1997-05-30 | 2004-01-15 | Celltech Therapeutics Ltd | ANTI-INFLAMMATORY TYROSINE DERIVATIVES |
ES2206953T3 (en) | 1997-06-23 | 2004-05-16 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF THE CELLULAR ADHERENCE MEDIATED BY ALFA 4-BETA |
PL338506A1 (en) | 1997-07-31 | 2000-11-06 | Elan Pharm Inc | Compounds inhibiting adhesion of leucocytes occuring through the mediation of vla-4 |
CN1265672A (en) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by VLA-4 |
AR016133A1 (en) | 1997-07-31 | 2001-06-20 | Wyeth Corp | CARBAMILOXI COMPOUND INHIBITING THE ADHESION OF LEUKOCYTES THROUGH VLA-4, COMPOUNDS THAT ARE DRUGS OF THESE COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD FOR SETTING VLA-4 TO A BIOLOGICAL SAMPLE, METHOD FOR THE TREATMENT OF A TREATMENT |
BR9811573A (en) | 1997-07-31 | 2000-09-19 | Elan Pharm Inc | Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion |
ZA986827B (en) | 1997-07-31 | 2000-05-02 | Athena Neurosciences Inc | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4. |
CN1265670A (en) | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | Dipeptide and related compounds which inhibit leukocyte adhesion medicated by VLA-4 |
ATE327245T1 (en) | 1997-07-31 | 2006-06-15 | Elan Pharm Inc | COMPOUNDS CONTAINING A 4-AMINO-PHENYLALANINE GROUP WHICH INHIBIT VLA-4-MEDIATED ADHESION OF LEUKOCYTES |
HUP0002682A3 (en) | 1997-07-31 | 2001-12-28 | American Home Products Corp Ma | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 |
RU2220950C2 (en) | 1997-08-22 | 2004-01-10 | Ф.Хоффманн-Ля Рош Аг | N-alkanoylphenylalanine derivatives |
AU742928C (en) | 1997-08-22 | 2003-02-20 | F. Hoffmann-La Roche Ag | N-alkanoylphenylalanine derivatives |
US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
WO1999026922A1 (en) | 1997-11-21 | 1999-06-03 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
WO1999026921A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | SUBSTITUTED β-ALANINE DERIVATIVES AS CELL ADHESION INHIBITORS |
JP2001523711A (en) | 1997-11-24 | 2001-11-27 | メルク エンド カムパニー インコーポレーテッド | Cyclic amino acid derivatives as cell adhesion inhibitors |
US6197794B1 (en) | 1998-01-08 | 2001-03-06 | Celltech Therapeutics Limited | Phenylalanine derivatives |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
WO1999043642A1 (en) | 1998-02-26 | 1999-09-02 | Celltech Therapeutics Limited | Phenylalanine derivatives as inhibitors of alpha4 integrins |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
GB9812088D0 (en) | 1998-06-05 | 1998-08-05 | Celltech Therapeutics Ltd | Chemical compounds |
WO1999064395A1 (en) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
ATE261932T1 (en) | 1998-12-22 | 2004-04-15 | Tanabe Seiyaku Co | INHIBITORS OF ALPHA-4 BETA-1-MEDIATED CELL ADHESION |
GB2354440A (en) | 1999-07-20 | 2001-03-28 | Merck & Co Inc | Aryl amides as cell adhesion inhibitors |
WO2001012183A1 (en) | 1999-08-16 | 2001-02-22 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
AU6909300A (en) | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
WO2001021584A1 (en) | 1999-09-24 | 2001-03-29 | Genentech, Inc. | Tyrosine derivatives |
US20040198833A1 (en) | 2000-08-31 | 2004-10-07 | Bender David Michael | Acetylenic sulfonamide derivatives |
-
2001
- 2001-08-21 MY MYPI20013917A patent/MY129000A/en unknown
- 2001-08-27 IL IL15430501A patent/IL154305A0/en unknown
- 2001-08-27 ZA ZA200301039A patent/ZA200301039B/en unknown
- 2001-08-27 PL PL365668A patent/PL206656B1/en unknown
- 2001-08-27 WO PCT/US2001/026594 patent/WO2002018320A2/en active IP Right Grant
- 2001-08-27 JP JP2002523438A patent/JP3899022B2/en not_active Expired - Fee Related
- 2001-08-27 CN CNB018149871A patent/CN1229334C/en not_active Expired - Fee Related
- 2001-08-27 MX MXPA03001837A patent/MXPA03001837A/en active IP Right Grant
- 2001-08-27 US US10/333,985 patent/US7026501B2/en not_active Expired - Fee Related
- 2001-08-27 NZ NZ524043A patent/NZ524043A/en not_active IP Right Cessation
- 2001-08-27 RU RU2003105885/04A patent/RU2250895C2/en not_active IP Right Cessation
- 2001-08-27 KR KR10-2003-7001993A patent/KR100528049B1/en not_active IP Right Cessation
- 2001-08-27 DK DK01966246T patent/DK1315694T3/en active
- 2001-08-27 AU AU2001286778A patent/AU2001286778B2/en not_active Ceased
- 2001-08-27 BR BR0113629-1A patent/BR0113629A/en active Search and Examination
- 2001-08-27 SI SI200130351T patent/SI1315694T1/en unknown
- 2001-08-27 CZ CZ20030487A patent/CZ303460B6/en not_active IP Right Cessation
- 2001-08-27 ES ES01966246T patent/ES2240509T3/en not_active Expired - Lifetime
- 2001-08-27 EP EP01966246A patent/EP1315694B1/en not_active Expired - Lifetime
- 2001-08-27 HU HU0302693A patent/HUP0302693A3/en unknown
- 2001-08-27 PT PT01966246T patent/PT1315694E/en unknown
- 2001-08-27 DE DE60109943T patent/DE60109943T2/en not_active Expired - Lifetime
- 2001-08-27 CA CA 2418054 patent/CA2418054C/en not_active Expired - Fee Related
- 2001-08-27 AU AU8677801A patent/AU8677801A/en active Pending
- 2001-08-27 AT AT01966246T patent/ATE292615T1/en active
- 2001-08-31 TW TW090121581A patent/TWI224587B/en not_active IP Right Cessation
- 2001-08-31 AR ARP010104172A patent/AR034556A1/en active IP Right Grant
-
2003
- 2003-02-05 IL IL154305A patent/IL154305A/en not_active IP Right Cessation
- 2003-02-25 NO NO20030885A patent/NO327861B1/en not_active IP Right Cessation
- 2003-07-11 HK HK03105043.3A patent/HK1052684B/en not_active IP Right Cessation
-
2005
- 2005-07-13 US US11/179,729 patent/US7456217B2/en not_active Expired - Fee Related
-
2008
- 2008-10-07 US US12/247,129 patent/US7671090B2/en not_active Expired - Fee Related
-
2010
- 2010-01-07 US US12/683,648 patent/US7872151B2/en not_active Expired - Fee Related
- 2010-12-08 US US12/962,707 patent/US8501809B2/en not_active Expired - Fee Related
-
2013
- 2013-07-03 US US13/934,405 patent/US20130289109A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999036393A1 (en) * | 1998-01-20 | 1999-07-22 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8222405B2 (en) | 2000-08-18 | 2012-07-17 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US7153963B2 (en) | 2000-08-18 | 2006-12-26 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US7872125B2 (en) | 2000-08-18 | 2011-01-18 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US8426588B2 (en) | 2000-08-18 | 2013-04-23 | Ajinomoto Co, Inc. | Phenylalanine derivatives |
US7772249B2 (en) | 2001-02-08 | 2010-08-10 | Eisai R&D Management Co., Ltd. | Imidazo[1,2-b]pyridazine compound |
US7285666B2 (en) | 2001-04-27 | 2007-10-23 | Eisai R&D Management Co., Ltd. | Pyrazolo[1,5-a] pyridines and medicines containing the same |
US7091215B2 (en) | 2001-04-27 | 2006-08-15 | Eisai Co., Ltd. | Pyrazolo[1,5-a]pyridines and medicines containing the same |
US7625925B2 (en) | 2001-04-27 | 2009-12-01 | Eisai R&D Management Co., Ltd | Pyrazolo[1,5-a]pyridines and medicines containing the same |
WO2003072536A1 (en) * | 2002-02-28 | 2003-09-04 | Tanabe Seiyaku Co., Ltd. | A process for preparing a phenylalanine derivative and intermediates thereof |
US7476758B2 (en) | 2002-02-28 | 2009-01-13 | Mitsubishi Tanbe Pharma Corporation | Process for preparing a phenylalanine derivative and intermediates thereof |
WO2004014844A3 (en) * | 2002-08-09 | 2005-04-28 | Transtech Pharma Inc | Aryl and heteroaryl compounds and methods to modulate coagulation |
JP2005535710A (en) * | 2002-08-09 | 2005-11-24 | トランス テック ファーマ,インコーポレイテッド | Aryl and heteroaryl compounds and methods for modulating coagulation |
US7122580B2 (en) | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
WO2004014844A2 (en) * | 2002-08-09 | 2004-02-19 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
US7323569B2 (en) | 2002-10-22 | 2008-01-29 | Eisai R&D Management Co., Ltd. | 7-phenylpyrazolopyridine compounds |
KR100984085B1 (en) | 2002-10-22 | 2010-09-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 7-phenyl pyrazolopyridine compounds |
WO2004037822A1 (en) * | 2002-10-22 | 2004-05-06 | Eisai Co., Ltd. | 7-phenyl pyrazolopyridine compounds |
US7176216B2 (en) | 2002-10-22 | 2007-02-13 | Eisai Co., Ltd. | 7-phenylpyrazolopyridine compounds |
WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
WO2005014533A3 (en) * | 2003-08-08 | 2005-04-07 | Transtech Pharma Inc | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014534A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
WO2005014533A2 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US7459472B2 (en) | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
US7544699B2 (en) | 2003-08-08 | 2009-06-09 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
US7345049B2 (en) | 2003-12-22 | 2008-03-18 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US8309561B2 (en) | 2003-12-22 | 2012-11-13 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
US7425554B2 (en) | 2003-12-26 | 2008-09-16 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic)substituted benzene compounds |
WO2006068058A1 (en) | 2004-12-20 | 2006-06-29 | Eisai R & D Management Co., Ltd. | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine |
US7910734B2 (en) | 2004-12-20 | 2011-03-22 | Eisai R&D Management Co., Ltd. | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine |
US7410971B2 (en) | 2004-12-24 | 2008-08-12 | Eisai R&D Management Co., Ltd. | 1,2-di(cyclic)substituted benzene compounds |
US7732614B2 (en) | 2005-06-09 | 2010-06-08 | Ucb S.A. | 2,6-quinolinyl derivatives, processes for preparing them and their uses |
WO2007060408A3 (en) * | 2005-11-23 | 2007-08-02 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
WO2007060408A2 (en) * | 2005-11-23 | 2007-05-31 | Astrazeneca Ab | L-phenylalanine derivatives and their use as integrin antagonists |
EA019879B1 (en) * | 2005-12-29 | 2014-07-30 | Лексикон Фармасьютикалз, Инк. | Multicyclic amino acid derivatives, pharmaceutical composition containing them and method of treatment using these derivatives |
WO2007074456A3 (en) * | 2005-12-29 | 2008-05-29 | Yeda Res & Dev | Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids |
EP2386547A1 (en) * | 2005-12-29 | 2011-11-16 | Lexicon Pharmaceuticals, Inc. | Multicyclic amino acid derivatives and methods of their use |
WO2007074456A2 (en) * | 2005-12-29 | 2007-07-05 | Yeda Research And Development Co.Ltd. | Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids |
WO2007089335A3 (en) * | 2005-12-29 | 2007-10-11 | Lexicon Genetics Inc | Multicyclic amino acid derivatives and methods of their use |
US8808698B2 (en) * | 2006-02-03 | 2014-08-19 | The Regents Of The University Of California | Methods for inhibition of lymphangiogenesis and tumor metastasis |
WO2007091046A1 (en) * | 2006-02-09 | 2007-08-16 | Astrazeneca Ab | Chemical compounds |
US8431603B2 (en) | 2008-04-15 | 2013-04-30 | Eisai R&D Management Co., Ltd. | 3-phenylpyrazolo[5,1-b]thiazole compounds |
US8530504B2 (en) | 2009-10-08 | 2013-09-10 | Eisai R&D Management Co., Ltd. | Pyrazolothiazole compound |
WO2011048091A1 (en) | 2009-10-21 | 2011-04-28 | Glaxo Group Limited | Process for preparing a phenylalanine derivative |
US20120203023A1 (en) * | 2009-10-21 | 2012-08-09 | Joseph Paul Adams | Process For Preparing A Phenylalanine Derivative |
US11116760B2 (en) | 2018-10-30 | 2021-09-14 | Gilead Sciences, Inc. | Quinoline derivatives |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
US11224600B2 (en) | 2018-10-30 | 2022-01-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1315694B1 (en) | Inhibitors of alpha 4 mediated cell adhesion | |
AU2001286778A1 (en) | Inhibitors of alpha4 mediated cell adhesion | |
AU749568B2 (en) | Inhibitors of alpha4 mediated cell adhesion | |
CA2305463C (en) | Aminobutanoic acid derivatives | |
JP4233353B2 (en) | Pharmaceutical composition | |
KR20020063906A (en) | 4-pyrimidinyl-n-acyl-l-phenylalanines | |
WO2006064757A1 (en) | Aminocarboxylic acid derivative and medicinal use thereof | |
WO2008053913A1 (en) | Sulfonylurea derivative capable of selectively inhibiting mmp-13 | |
JP3646062B2 (en) | Heteroaryl-substituted thiol-type inhibitors of endothelin converting enzyme | |
JPWO2002102780A1 (en) | Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient | |
JP6301371B2 (en) | Substituted bisphenylbutanoic acid derivatives as NEP inhibitors with improved in vivo efficacy | |
MXPA06007008A (en) | Novel compounds. | |
MXPA00007138A (en) | INHIBITORS OF&agr;4 MEDIATED CELL ADHESION | |
JP2004026679A (en) | Dihydronaphthalene derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200300130 Country of ref document: VN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2418054 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 154305 Country of ref document: IL Ref document number: 2001286778 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/01039 Country of ref document: ZA Ref document number: 200301039 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 524043 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037001993 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-487 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 00227/DELNP/2003 Country of ref document: IN Ref document number: 227/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10333985 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002523438 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/001837 Country of ref document: MX Ref document number: 2001966246 Country of ref document: EP Ref document number: 1-2003-500091 Country of ref document: PH Ref document number: 018149871 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2003105885 Country of ref document: RU Kind code of ref document: A Ref country code: RU Ref document number: RU A |
|
WWP | Wipo information: published in national office |
Ref document number: 2001966246 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-487 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037001993 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 524043 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 524043 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001966246 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001286778 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020037001993 Country of ref document: KR |